Kranzler H R, Modesto-Lowe V, Van Kirk J
Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030-2103, USA.
Neuropsychopharmacology. 2000 May;22(5):493-503. doi: 10.1016/S0893-133X(99)00135-9.
This study compared the effects of nefazodone, a serotonergic antidepressant, with the opioid antagonist naltrexone, and an inactive placebo in 183 alcohol-dependent subjects receiving weekly relapse prevention psychotherapy. Following a single-blind, placebo lead-in period, subjects were randomly assigned to receive study medication, which they took under double-blind conditions for 11 weeks. Naltrexone treatment was associated with significantly more adverse neuropsychiatric and gastrointestinal effects, poorer compliance, and a greater rate of treatment attrition. There were no reliable between-group differences in drinking behavior. These results indicate that nefazodone is not efficacious for treatment of alcohol dependence. Furthermore, the clinical utility of naltrexone seems to be limited by its adverse effects, a finding that has important implications for efforts to develop medications to treat alcohol dependence.
本研究比较了血清素能抗抑郁药奈法唑酮、阿片类拮抗剂纳曲酮及无活性安慰剂对183名接受每周一次预防复发心理治疗的酒精依赖者的影响。在单盲、安慰剂导入期后,受试者被随机分配接受研究药物,他们在双盲条件下服用11周。纳曲酮治疗与明显更多的不良神经精神和胃肠道效应、较差的依从性以及更高的治疗脱落率相关。饮酒行为方面,组间无可靠差异。这些结果表明,奈法唑酮对酒精依赖治疗无效。此外,纳曲酮的临床效用似乎受其不良反应限制,这一发现对开发治疗酒精依赖药物的努力具有重要意义。